A non‐covalent inhibitor XMU‐MP‐3 overrides ibrutinib‐resistant Btk(C481S) mutation in B‐cell malignancies

BACKGROUND AND PURPOSE: Bruton's tyrosine kinase (BTK) plays a key role in B‐cell receptor signalling by regulating cell proliferation and survival in various B‐cell malignancies. Covalent low‐MW BTK kinase inhibitors have shown impressive clinical efficacy in B‐cell malignancies. However, the...

Full description

Saved in:
Bibliographic Details
Published in:Br J Pharmacol
Main Authors: Gui, Fu, Jiang, Jie, He, Zhixiang, Li, Li, Li, Yunzhan, Deng, Zhou, Lu, Yue, Wu, Xinrui, Chen, Guyue, Su, Jingyi, Song, Siyang, Zhang, Yue‐Ming, Yun, Cai‐Hong, Huang, Xin, Weisberg, Ellen, Zhang, Jianming, Deng, Xianming
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2019
Subjects:
Research Papers
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6932946/
https://ncbi.nlm.nih.gov/pubmed/31364164
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14809
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items